Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADPT Adaptive Biotechnologies	$10.38 -0.9%	$9.03	$3.17 ▼ $10.87	$1.59B	1.8	1.57 million shs	1.77 million shs
ALMS Alumis	$2.86 -5.0%	$4.26	$2.81 ▼ $13.53	$163.76M	N/A	410,806 shs	1.60 million shs
AMPH Amphastar Pharmaceuticals	$24.56 -3.1%	$24.77	$22.64 ▼ $53.96	$1.19B	0.77	491,996 shs	672,732 shs
EVO Evotec	$3.76 -5.3%	$4.05	$2.84 ▼ $5.64	$1.41B	1.66	134,314 shs	166,023 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADPT Adaptive Biotechnologies	-0.86%	+0.58%	+14.19%	+23.57%	+237.01%
ALMS Alumis	-4.98%	-8.92%	-40.17%	-23.73%	+285,999,900.00%
AMPH Amphastar Pharmaceuticals	-3.08%	-4.88%	+1.66%	-13.18%	-38.68%
EVO Evotec	-5.29%	-11.94%	-6.23%	+7.12%	-7.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADPT Adaptive Biotechnologies	2.5692 of 5 stars	1.4	1.0	4.2	2.0	2.5	0.6
ALMS Alumis	2.7373 of 5 stars	3.6	0.0	0.0	2.1	1.7	1.3
AMPH Amphastar Pharmaceuticals	4.2255 of 5 stars	3.1	1.0	3.7	2.7	4.2	1.3
EVO Evotec	2.0541 of 5 stars	3.2	4.0	0.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADPT Adaptive Biotechnologies	2.86	Moderate Buy	$10.57	1.84% Upside
ALMS Alumis	3.22	Buy	$22.86	699.20% Upside
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	31.65% Upside
EVO Evotec	2.40	Hold	$5.93	57.80% Upside

Current Analyst Ratings Breakdown

Latest ALMS, ADPT, AMPH, and EVO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ADPT Adaptive Biotechnologies	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/10/2025	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$18.00
5/15/2025	EVO Evotec	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/15/2025	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$26.00 ➝ $25.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/6/2025	ADPT Adaptive Biotechnologies	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$11.00 ➝ $13.00
5/5/2025	ADPT Adaptive Biotechnologies	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$7.00 ➝ $9.00
5/2/2025	ADPT Adaptive Biotechnologies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $10.00
4/30/2025	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/24/2025	EVO Evotec	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sell ➝ Hold

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADPT Adaptive Biotechnologies	$178.96M	8.81	N/A	N/A	$1.37 per share	7.58
ALMS Alumis	N/A	N/A	N/A	N/A	$5.51 per share	N/A
AMPH Amphastar Pharmaceuticals	$731.97M	1.58	$4.85 per share	5.06	$15.23 per share	1.61
EVO Evotec	$862.40M	1.55	N/A	N/A	$2.91 per share	1.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADPT Adaptive Biotechnologies	-$159.49M	-$0.96	N/A	N/A	N/A	-74.84%	-62.79%	-24.55%	7/30/2025 (Estimated)
ALMS Alumis	-$294.23M	N/A	0.00	N/A	N/A	N/A	-406.27%	-107.29%	8/12/2025 (Estimated)
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.90	7.47	6.60	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
EVO Evotec	-$212.18M	N/A	0.00	N/A	N/A	-26.34%	-21.51%	-10.54%	8/13/2025 (Estimated)

Latest ALMS, ADPT, AMPH, and EVO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/14/2025	Q1 2025	ALMS Alumis	-$1.47	-$1.82	-$0.35	-$1.82	N/A	N/A
5/1/2025	Q1 2025	ADPT Adaptive Biotechnologies	-$0.28	-$0.20	+$0.08	-$0.20	$42.13 million	$52.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADPT Adaptive Biotechnologies	N/A	N/A	N/A	N/A	N/A
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EVO Evotec	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADPT Adaptive Biotechnologies	N/A	2.92	2.82
ALMS Alumis	N/A	3.73	3.73
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
EVO Evotec	0.46	2.03	1.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADPT Adaptive Biotechnologies	99.17%
ALMS Alumis	N/A
AMPH Amphastar Pharmaceuticals	65.09%
EVO Evotec	5.81%

Insider Ownership

Company	Insider Ownership
ADPT Adaptive Biotechnologies	6.40%
ALMS Alumis	N/A
AMPH Amphastar Pharmaceuticals	27.50%
EVO Evotec	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADPT Adaptive Biotechnologies	790	151.92 million	142.19 million	Optionable
ALMS Alumis	N/A	54.41 million	N/A	N/A
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
EVO Evotec	4,827	355.11 million	351.56 million	Not Optionable

ALMS, ADPT, AMPH, and EVO Headlines

Recent News About These Companies

Evotec (NASDAQ:EVO) Sees Large Volume Increase - Still a Buy?

June 17, 2025 | marketbeat.com

Mursla Bio introduces AI precision medicine platform built on organ-specific EV isolation from blood

June 17, 2025 | cambridgenetwork.co.uk

Evotec (NASDAQ:EVO) Shares Gap Down - Here's Why

June 16, 2025 | marketbeat.com

Evotec (NASDAQ:EVO) Shares Gap Up - What's Next?

June 12, 2025 | marketbeat.com

New NLRP3 inflammasome inhibitors disclosed in Evotec patent

June 6, 2025 | bioworld.com

BDK Advokati Advises Entec Evotec on Acquisition of Fortaco Gruza

June 3, 2025 | ceelegalmatters.com

Evotec SE Announces AGM Results and Strategic Outlook

June 3, 2025 | tipranks.com

Evotec SE (NASDAQ:EVO) Shares Sold by Wellington Management Group LLP

June 3, 2025 | marketbeat.com

Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

May 31, 2025 | marketbeat.com

Evotec (NASDAQ:EVO) Stock Price Down 6.8% - Should You Sell?

May 28, 2025 | marketbeat.com

Fortaco sells Serbian marine equipment unit to Evotec

May 26, 2025 | seenews.com

Evotec (NASDAQ:EVO) Shares Gap Up - Still a Buy?

May 25, 2025 | marketbeat.com

Evotec (NASDAQ:EVO) Shares Gap Down - Should You Sell?

May 24, 2025 | marketbeat.com

Advancing GPCR drug discovery with fragment screening using GCI technology

May 23, 2025 | msn.com

Evotec Net Loss Widens In Q1; Confirms FY25, FY28 Revenue Guidance

May 7, 2025 | nasdaq.com

Evotec Receives $2.5M Grant from the Gates Foundation

May 7, 2025 | contractpharma.com

Evotec SE (NASDAQ:EVO) Q1 2025 Earnings Call Transcript

May 7, 2025 | msn.com

Evotec SE: Evotec Earnings: Solid Results Amid Market Softness; Biologics Segment Remains a Key Growth Driver

May 7, 2025 | finance.yahoo.com

Germany's Evotec wins grant worth $2.5m from Gates Foundation for TB

May 7, 2025 | msn.com

Evotec SE (EVO) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Embracing ...

May 7, 2025 | finance.yahoo.com

Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments

May 7, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALMS, ADPT, AMPH, and EVO Company Descriptions

Adaptive Biotechnologies NASDAQ:ADPT

$10.38 -0.09 (-0.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$10.12 -0.27 (-2.55%)

As of 06/20/2025 07:52 PM Eastern

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Alumis NASDAQ:ALMS

$2.86 -0.15 (-4.98%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.88 +0.02 (+0.87%)

As of 06/20/2025 07:46 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.56 -0.78 (-3.08%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$24.56 0.00 (0.00%)

As of 06/20/2025 06:13 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Evotec NASDAQ:EVO

$3.76 -0.21 (-5.29%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.78 +0.03 (+0.66%)

As of 06/20/2025 04:04 PM Eastern

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time